Before the diagnosis of LM, 4 patients (2.9%) received ALK‐inhibitors, 50 patients (36.8%) received at least one line of EGFR‐TKI therapy, and 27 patients (19.9%) underwent WBRT for brain metastases (BMs). This evidence concerns the gene EGFR and burning mouth syndrome.